Preempting Coronary Ischemia – Expanding the Spectrum of Cardiac Biomarkers
MPO testing provides prognostic information in addition to troponin and hsCRP testing, revealing a more complete clinical picture of the CVD patient. It may also add incremental value when used with other biomarkers, particularly in troponin-negative patients, enabling treatment before more severe myocardial damage occurs.
Reliable Answers to Critical Cardiac Questions
As a recognized worldwide leader in CVD testing, Siemens Healthcare Diagnostics offers MPO testing across multiple instrument solutions to help provide a more complete clinical picture of the CVD patient.
- Fully automated, no-pretreatment MPO
- Can be run on same instrument along with other cardiac markers
- Same turnaround time as troponin
Myeloperoxidase assays are available on the following systems from Siemens Healthcare Diagnostics: